Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
24.44
-0.18 (-0.73%)
At close: Jan 28, 2026, 4:00 PM EST
24.20
-0.24 (-0.98%)
Pre-market: Jan 29, 2026, 4:06 AM EST
Ultragenyx Pharmaceutical Revenue
Ultragenyx Pharmaceutical had revenue of $159.93M in the quarter ending September 30, 2025, with 14.65% growth. This brings the company's revenue in the last twelve months to $630.60M, up 20.63% year-over-year. In the year 2024, Ultragenyx Pharmaceutical had annual revenue of $560.23M with 29.01% growth.
Revenue (ttm)
$630.60M
Revenue Growth
+20.63%
P/S Ratio
3.78
Revenue / Employee
$487,325
Employees
1,294
Market Cap
2.35B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 560.23M | 125.98M | 29.01% |
| Dec 31, 2023 | 434.25M | 70.92M | 19.52% |
| Dec 31, 2022 | 363.33M | 11.92M | 3.39% |
| Dec 31, 2021 | 351.41M | 80.38M | 29.66% |
| Dec 31, 2020 | 271.03M | 167.32M | 161.32% |
| Dec 31, 2019 | 103.71M | 52.22M | 101.41% |
| Dec 31, 2018 | 51.50M | 48.88M | 1,871.48% |
| Dec 31, 2017 | 2.61M | 2.48M | 1,863.91% |
| Dec 31, 2016 | 133.00K | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sarepta Therapeutics | 2.41B |
| Harmony Biosciences Holdings | 825.94M |
| Galapagos NV | 336.64M |
| Wave Life Sciences | 109.23M |
| Ocular Therapeutix | 55.78M |
| Ascentage Pharma Group International | 54.52M |
| Recursion Pharmaceuticals | 43.69M |
| Mesoblast | 17.20M |
RARE News
- 5 days ago - Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 days ago - Ultragenyx Stock Declines After Missing Primary Endpoints on its Phase III Orbit and Cosmic Studies - PRNewsWire
- 6 days ago - Ultragenyx: From Bone To Brain, Capitulation Creates A Free Option On The Neuro Pipeline - Seeking Alpha
- 16 days ago - Ultragenyx Pharmaceutical Inc. (RARE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 16 days ago - Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa) - GlobeNewsWire
- 4 weeks ago - Ultragenyx Pharmaceutical, Inc. Investigated by the Portnoy Law Firm - GlobeNewsWire
- 4 weeks ago - Ultragenyx Bone Drug Stumbles In Phase 3, But Key Catalysts Remain - Benzinga